Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 6 Neoplasms 5 Neoplasm Metastasis 4 Ovarian Neoplasms 3 Endometrial Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Adenocarcinoma 1 Advanced Breast Cancer 1

Interventions

Temozolomide 140 Bevacizumab 80 Radiotherapy 69 Magnetic Resonance Spectroscopy 22 Radiation 18 Irinotecan 18 pembrolizumab 17 Lomustine 16 Carmustine 15 Surgical Procedures, Operative 13 Nivolumab 11 Erlotinib Hydrochloride 11 sargramostim 9 Thalidomide 9 Specimen Handling 9 Chemotherapy, Adjuvant 9 Aminolevulinic Acid 9 Carboplatin 8 Cilengitide 7 Sunitinib 6 Immunoglobulin G 6 Etoposide 6 Disulfides 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Radiotherapy, Intensity-Modulated 5 Radiosurgery 5 Metformin 5 Imatinib Mesylate 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04740190 2025-06-11

TAC-GReD

The University of Hong Kong

Phase 2 Completed

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡